Brokerages Set Johnson & Johnson (JNJ) PT at $144.45
Johnson & Johnson (NYSE:JNJ) has been assigned an average rating of “Buy” from the fourteen research firms that are covering the firm, Marketbeat Ratings reports. Five research analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $146.40.
Several research analysts recently weighed in on the company. BMO Capital Markets upped their price target on Johnson & Johnson from $154.00 to $157.00 and gave the company an “outperform” rating in a research report on Wednesday. Credit Suisse Group upped their price target on Johnson & Johnson from $151.00 to $152.00 and gave the company an “outperform” rating in a research report on Wednesday. Morgan Stanley upped their price target on Johnson & Johnson from $134.00 to $145.00 and gave the company an “equal weight” rating in a research report on Wednesday. Raymond James upped their price target on Johnson & Johnson from $145.00 to $147.00 and gave the company an “outperform” rating in a research report on Wednesday. Finally, Zacks Investment Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $155.00 price target on the stock in a research report on Wednesday, March 27th.
A number of large investors have recently bought and sold shares of JNJ. Evolution Wealth Advisors LLC purchased a new position in Johnson & Johnson in the fourth quarter valued at about $40,000. Crewe Advisors LLC grew its stake in Johnson & Johnson by 75.0% in the fourth quarter. Crewe Advisors LLC now owns 350 shares of the company’s stock valued at $45,000 after purchasing an additional 150 shares in the last quarter. Horan Securities Inc. grew its stake in Johnson & Johnson by 122.3% in the fourth quarter. Horan Securities Inc. now owns 438 shares of the company’s stock valued at $56,000 after purchasing an additional 241 shares in the last quarter. First Bank & Trust grew its stake in Johnson & Johnson by 30.4% in the first quarter. First Bank & Trust now owns 399 shares of the company’s stock valued at $56,000 after purchasing an additional 93 shares in the last quarter. Finally, Stone House Investment Management LLC purchased a new position in Johnson & Johnson in the first quarter valued at about $58,000. 67.32% of the stock is currently owned by hedge funds and other institutional investors.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 16th. The company reported $2.10 earnings per share for the quarter, beating the consensus estimate of $2.03 by $0.07. The firm had revenue of $20.02 billion for the quarter, compared to analyst estimates of $19.55 billion. Johnson & Johnson had a return on equity of 35.79% and a net margin of 17.99%. Johnson & Johnson’s quarterly revenue was up .1% on a year-over-year basis. During the same period in the previous year, the firm earned $2.06 earnings per share. Analysts expect that Johnson & Johnson will post 8.6 EPS for the current year.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.